Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?A G Pallis
EORTC Elderly Task Force Member and Department of Medical Oncology, University General Hospital of Heraklion, Greece
Cancer Treat Rev 36:436-41. 2010
..Despite a growing body of data, further work is still needed to establish optimal strategies to care for this special population and prospective specific trials for older NSCLC patients are clearly needed...
EORTC elderly task force position paper: approach to the older cancer patientA G Pallis
European Organization for Research and Treatment of Cancer, Elderly Task Force, EORTC Headquarters, Avenue E Mounierlaan, 83 11, B 1200 Brussels, Belgium
Eur J Cancer 46:1502-13. 2010
..The purpose of this paper is to focus on the influence of age on cancer presentation and cancer management in older cancer patients and to provide suggestions on clinical trial development and methodology in this population...
Targeting tumor neovasculature in non-small-cell lung cancerAthanasios G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, Heraklion 71110, Crete, Greece Electronic address
Crit Rev Oncol Hematol 86:130-42. 2013
..The purpose of this paper is to present the current status of antiangiogenic therapies in the treatment of NSCLC and to discuss these issues...
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLCA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece Electronic address
Lung Cancer 80:120-30. 2013
..The purpose of this paper is to present the relevant clinical data, describe the predictive markers available for TKIs treatment in NSCLC, and describe the mechanisms associated with resistance to treatment with these agents...
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancerAthanasios G Pallis
Hellenic Oncology Research Group HORG, Athens, Greece
Clin Lung Cancer 13:129-35. 2012
..The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC)...
Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of careAthanasios G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
Lung Cancer 75:269-74. 2012
....
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancerAthanasios G Pallis
Hellenic Oncology Research Group, 55 Lombardou str, 114 74 Athens, Greece
BMC Cancer 10:633. 2010
..To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
Are we treating enough elderly patients with early stage non-small cell lung cancer?A G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, Voutes Stavrakion Embranchement, 71305 Heraklion, Greece
Lung Cancer 74:149-54. 2011
..Given the lack of demonstrated benefit for the use of adjuvant RT it is also not recommended in older population...
Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancerA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece
Br J Cancer 105:1-8. 2011
..Use of other biomarkers remains investigational...
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumorsA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
Ann Oncol 22:1922-6. 2011
..A multidisciplinary approach to the senior adult cancer patient is mandatory, to assure optimal diagnosis and therapeutic management...
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research GroupA G Pallis
Hellenic Oncology Research Group, Athens, Greece
Ann Oncol 22:2448-55. 2011
..Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%-40% of cases occur in patients >70 years...
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapyA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
Lung Cancer 62:356-63. 2008
..One of its more common side effects is neutropenia. The association between the grade of DG-induced neutropenia and the clinical outcome was analyzed...
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysisN Maniadakis
Department of Health Services Management, National School of Public Health, Athens, Greece
Ann Oncol 21:1462-7. 2010
....
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancerA G Pallis
Breast Cancer Study Group, Hellenic Oncology Research Group HORG, Athens, Greece
Ann Oncol 23:1164-9. 2012
..The primary objective was to demonstrate superiority of combination treatment in terms of progression-free survival (PFS)...
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly populationA G Pallis
EORTC Headquarters, EORTC ETF, Avenue E Mounierlaan 83 11, Brussels, Belgium
Ann Oncol 21:692-706. 2010
..Prospective elderly-specific trials are needed...
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trialA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
Lung Cancer 55:101-7. 2007
..To evaluate the activity and toxicity of the sequential administration of docetaxel followed by gefitinib in patients with advanced non-small cell lung cancer (NSCLC)...
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerA G Pallis
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
Br J Cancer 97:1560-6. 2007
..The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study...
Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?A G Pallis
European Organization for Research and Treatment of Cancer, Elderly Task Force, EORTC Headquarters, Avenue E Mounierlaan, 83 11, B 1200 Brussels, Belgium
Eur J Cancer 46:1019-25. 2010
..In the present paper, we discuss the most commonly used and studied tools for the assessment of functional status of older cancer patients...
Targeted therapies in the treatment of advanced/metastatic NSCLCA G Pallis
EORTC Headquarters, EORTC ETF, Avenue E Mounierlaan, 83 11, Brussels B 1200, Belgium
Eur J Cancer 45:2473-87. 2009
..The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC...
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use programA G Pallis
Department of Medical Oncology, University Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
Lung Cancer 40:301-7. 2003
..Furthermore, ZD1839 showed a favorable toxicity profile, with the majority of adverse events being mild and reversible...
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patientsA G Pallis
EORTC Headquarters, EORTC Elderly Task Force, Brussels, Belgium
Cancer Treat Rev 36:83-90. 2010
..Despite a growing body of data, further work is still needed to establish optimal strategies to care for this special population and prospective specific trials for older colon cancer patients are clearly needed...
Small cell ovarian cancer in adolescents: report of two cases and review of the literatureM Rovithi
Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 711 10 Heraklion, Crete, Greece
Case Report Med 2011:749516. 2011
..Herein, we report two cases of small cell carcinoma of the ovaries along with a review of the relevant literature...
The inflammatory bowel disease questionnaire: a review of its national validation studiesA G Pallis
Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Crete, Greece
Inflamm Bowel Dis 10:261-9. 2004
..Assessing HRQoL in patients with IBD is an ever-increasing practice, especially in clinical trials. IBDQ was proven to be valid and reliable in several cultural and linguistic milieus when appropriate validation procedures were applied...